DEF: Alnylam Pharmaceuticals Sets May 20, 2026 Annual Meeting

Alnylam Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 20, 2026, to elect directors, approve executive compensation, and ratify auditors.

Summary

• Alnylam Pharmaceuticals, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 20, 2026, at 10:30 a.m. Eastern Time.
• Stockholders of record as of March 25, 2026, are entitled to vote.
• The meeting agenda includes the election of three Class I directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2026.
• The company is providing proxy materials primarily via the internet, with a Notice of Internet Availability being mailed around April 6, 2026.
• Stockholders can vote via the internet, telephone, or mail before the meeting, or virtually during the meeting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting strong financial performance, strategic progress, and robust corporate governance, though it also details director resignations and executive compensation adjustments.

Positives

• The company is holding its annual meeting to engage with stockholders.
• The company has a clear process for director nominations and evaluations.
• Strong corporate governance practices are in place, with a majority of independent directors and fully independent board committees.
• The company emphasizes alignment with long-term stockholders through stock ownership guidelines and a clawback policy.
• The company has a robust ESG strategy with clear pillars and reported progress in 2025.
• Executive compensation is heavily weighted towards performance-based and at-risk components, aligning with stockholder interests.
• The company achieved profitability for the first time in its history in 2025.
• Global net product revenues increased by 81% in 2025, reaching nearly $3 billion.
• The company's three-year total stockholder return (TSR) was 67% and five-year TSR was 206%.

Negatives

• Two directors, Michael W. Bonney and Carolyn R. Bertozzi, resigned from the board in December 2025.
• The company's CEO, Dr. Greenstreet, is not considered an independent director.
• The pay ratio of CEO to median employee increased in 2025 due to higher equity grants for the CEO.

Risks

• Alnylam faces risks related to launching, marketing, and selling its approved products globally.
• Risks include challenges in preclinical and clinical research and development, manufacturing, and drug supply.
• Regulatory reviews, approvals, and compliance with requirements pose potential risks.
• The company is exposed to risks associated with intellectual property protection, competition, cybersecurity, and the adoption of artificial intelligence.
• Litigation and government investigations are also identified risks.
• The company must manage growth, operating expenses, and global capability expansion effectively.
• Optimizing capital structure and capital allocation are ongoing considerations.
• Dependence on third parties for development and commercialization of certain products presents a risk.

Future Outlook

The company is focused on its Alnylam 2030 strategy, aiming for leadership in TTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. This includes advancing its pipeline of RNAi therapeutics and scaling global operations.

Management Comments

• "We invite you to attend the 2026 Annual Meeting of Stockholders of Alnylam Pharmaceuticals, Inc., which will be held online on Wednesday, May 20, 2026, beginning at 10:30 a.m., Eastern Time."
• "On behalf of our Board of Directors, thank you for your continued support of Alnylam."
• "Our board believes that our current leadership structure is appropriate because it provides an effective balance between strategy development and independent leadership and management oversight."
• "Our board and nominating and corporate governance committee continue to believe that the classified board structure aligns with the companys long-term orientation and enables the board to provide appropriate and expert oversight of management over the course of the multi-year life cycles of our clinical development programs, which our board believes ultimately drives the creation of sustainable stockholder value."
• "We believe that our executive compensation program does not encourage excessive or inappropriate risk-taking and is not reasonably likely to have a material adverse effect on the company."
• "2025 was a transformational year for Alnylam. We secured regulatory approvals in the U.S. and throughout the globe for AMVUTTRA for the treatment of ATTR-CM, which is rapidly becoming our flagship commercial franchise."
• "As the PC&C committee and board reflected on these successes and growth ambitions, they were mindful of the increasing scope and complexity of the roles and responsibilities of our executive officers and the need to make adjustments to our compensation framework as necessary to ensure leadership continuity and focus during this critical inflection period for the company."

Industry Context

StockSavvy.ai notes that Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is holding its annual meeting amidst a period of significant growth, marked by key regulatory approvals and strong financial performance, including achieving profitability for the first time. The company's strategic focus on its 'Alnylam 2030' plan highlights its commitment to expanding its commercial franchise and advancing its pipeline in a competitive biotechnology landscape.

Management Changes

Corporate Governance

Related Party Transactions

• No related party transactions reportable under Item 404(a) of Regulation S-K have occurred since January 1, 2025.

Stakeholder Impact

• Shareholders will have the opportunity to vote on director elections, executive compensation, and auditor ratification, influencing corporate governance.
• Employees may be impacted by executive compensation decisions, particularly the retention incentives for key personnel.
• The company's commitment to ESG and patient access initiatives reflects a positive impact on communities and patients.

Next Steps

• Stockholders are encouraged to vote on the proposals before the annual meeting.
• The company will hold its virtual annual meeting on May 20, 2026.
• The company will continue to execute its Alnylam 2030 strategy.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting, detailing director nominations, executive compensation, and auditor ratification. While the company reports strong financial performance and strategic progress, there are no new material business developments or significant changes that would warrant a buy or sell recommendation based solely on this document. The focus is on governance and compensation, which are standard for this type of filing.

Keywords

Alnylam Pharmaceuticals, Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Independent Auditors, Corporate Governance, RNAi Therapeutics, Biotechnology, SEC Filing